中嘉博創(000889.SZ):上海峯幽減持數過半 累計減持1%股份
格隆匯12月10日丨中嘉博創(000889.SZ)公佈,持有公司股份2644.58萬股(佔公司總股本比例3.95%)的股東上海峯幽投資管理中心(普通合夥)(簡稱“上海峯幽”),計劃以集中競價和大宗交易方式減持股份合計不超過2644.58萬股。
2019年12月10日,公司收到第一大股東鷹溪谷的一致行動人上海峯幽的《股份減持計劃實施進展情況的告知函》,截至2019年12月10日,上海峯幽通過大宗交易及集中競價方式累計減持公司股份1454.22萬股,減持股份比例已達公司股份總數的1%,且減持計劃股份數量已過半。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.